Juliane Wurm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Juliane Wurm has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Petra Zimmermann
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
4 shared publications Lisa Kottanattu
Department of Paediatrics, Institute of Pediatrics of Southern Switzerland, EOC, Bellinzona, Switzerland
3 shared publications- Nicole Ritz
Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
3 shared publications Nina Schöbi
Division of Paediatric Infectious Diseases, Department of Paediatrics, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publicationsAnita Uka
Department Women-Mother-Child, Lausanne University Hospital, Lausanne
2 shared publicationsAnna Sandoni
Department of Epidemiology and Health Monitoring Robert Koch Institute Berlin Germany
2 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004323
Antibiotic overuse in children with viral infections: lessons from the SARS-CoV-2 pandemic
Background: Although COVID-19 is usually mild in children, antibiotics are frequently prescribed during hospitalisation, often without evidence of bacterial infection. Objective: To assess the frequency and predictors of antibiotic use in children hospitalised with SARS-CoV-2 infection in Switzerland. Methods: In this nationwide prospective study, children aged 0–18 years hospitalised with confirmed SARS-CoV-2 infection or symptoms compatible with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) between January 2022 and March 2023 were included. Univariable and multivariable logistic regression analyses were used to identify risk and protective factors for antibiotic use. A sensitivity analysis was conducted excluding high-risk patients. Results: Among 1944 hospitalised children, 586 (30%) received antibiotics. Of these, 71 (12%) had a clinically suspected bacterial infection without microbiological confirmation and 41 (7%) had microbiologically confirmed infection. Predictors of antibiotic use were microbiologically confirmed bacterial infection (aOR 138.08), clinically suspected bacterial infection (aOR 114.48), haematologic/oncologic disease (aOR 6.77), PIMS-TS (aOR 5.36), fever (aOR 2.98), neonatal age (aOR 2.80) and treatment in tertiary centres (aOR 1.65). After excluding high-risk patients, however, treatment in tertiary centres and PIMS-TS were no longer significant predictors in the sensitivity analysis. Respiratory distress/tachypnoea (aOR 0.72) and admission with confirmed SARS-CoV-2 as the primary diagnosis (aOR 0.42) were associated with lower antibiotic use in the primary analysis. After excluding high-risk patients, this association was no longer observed and nasal symptoms (aOR 0.68) and seizures (aOR 0.34) emerged as protective factors. Conclusion: Antibiotics were frequently prescribed to children hospitalised with SARS-CoV-2 despite limited evidence of bacterial infection. Our findings underscore the need to strengthen antimicrobial stewardship in paediatric COVID-19 care.
- 10 June 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004323
Open AccessAntibiotic overuse in children with viral infections: lessons from the SARS-CoV-2 pandemic
Background: Although COVID-19 is usually mild in children, antibiotics are frequently prescribed during hospitalisation, often without evidence of bacterial infection. Objective: To assess the frequency and predictors of antibiotic use in children hospitalised with SARS-CoV-2 infection in Switzerland. Methods: In this nationwide prospective study, children aged 0–18 years hospitalised with confirmed SARS-CoV-2 infection or symptoms compatible with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) between January 2022 and March 2023 were included. Univariable and multivariable logistic regression analyses were used to identify risk and protective factors for antibiotic use. A sensitivity analysis was conducted excluding high-risk patients. Results: Among 1944 hospitalised children, 586 (30%) received antibiotics. Of these, 71 (12%) had a clinically suspected bacterial infection without microbiological confirmation and 41 (7%) had microbiologically confirmed infection. Predictors of antibiotic use were microbiologically confirmed bacterial infection (aOR 138.08), clinically suspected bacterial infection (aOR 114.48), haematologic/oncologic disease (aOR 6.77), PIMS-TS (aOR 5.36), fever (aOR 2.98), neonatal age (aOR 2.80) and treatment in tertiary centres (aOR 1.65). After excluding high-risk patients, however, treatment in tertiary centres and PIMS-TS were no longer significant predictors in the sensitivity analysis. Respiratory distress/tachypnoea (aOR 0.72) and admission with confirmed SARS-CoV-2 as the primary diagnosis (aOR 0.42) were associated with lower antibiotic use in the primary analysis. After excluding high-risk patients, this association was no longer observed and nasal symptoms (aOR 0.68) and seizures (aOR 0.34) emerged as protective factors. Conclusion: Antibiotics were frequently prescribed to children hospitalised with SARS-CoV-2 despite limited evidence of bacterial infection. Our findings underscore the need to strengthen antimicrobial stewardship in paediatric COVID-19 care.
- 20 March 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (7) , 675-681
Clinical and Laboratory Biomarkers as Predictors of Severity in Pediatric Inflammatory Multisystem Syndrome-temporally Associated With SARS-CoV-2: Data From a Prospective Nationwide Surveillance Study in Switzerland
Background: PIMS-TS (pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2) is a rare but serious condition in children following SARS-CoV-2 infection, characterized by a range of clinical symptoms with varying severity. Understanding risk factors for severe PIMS-TS is crucial for appropriate and timely intervention. Objective: To identify factors associated with increased PIMS-TS severity in children. Methods: In this nationwide prospective observational study, epidemiological and clinical data was collected from children P < 0.001 and 66% versus 41%, P = 0.001, respectively. Compared with the non-ICU group, children in the ICU-severe group had lower lymphocyte counts, higher neutrophil-lymphocyte ratios, lower platelet counts, as well as higher C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin T and creatinine levels at admission. Lymphopenia and elevated troponin T levels at admission were associated with an increased risk of being in the ICU-severe group. Conclusion: The severity of PIMS-TS may be predicted using clinical symptoms and laboratory biomarkers, which help clinicians in decision-making and management of patients.
- 20 March 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (7) , 675-681
Clinical and Laboratory Biomarkers as Predictors of Severity in Pediatric Inflammatory Multisystem Syndrome-temporally Associated With SARS-CoV-2: Data From a Prospective Nationwide Surveillance Study in Switzerland
Background: PIMS-TS (pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2) is a rare but serious condition in children following SARS-CoV-2 infection, characterized by a range of clinical symptoms with varying severity. Understanding risk factors for severe PIMS-TS is crucial for appropriate and timely intervention. Objective: To identify factors associated with increased PIMS-TS severity in children. Methods: In this nationwide prospective observational study, epidemiological and clinical data was collected from children P < 0.001 and 66% versus 41%, P = 0.001, respectively. Compared with the non-ICU group, children in the ICU-severe group had lower lymphocyte counts, higher neutrophil-lymphocyte ratios, lower platelet counts, as well as higher C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin T and creatinine levels at admission. Lymphopenia and elevated troponin T levels at admission were associated with an increased risk of being in the ICU-severe group. Conclusion: The severity of PIMS-TS may be predicted using clinical symptoms and laboratory biomarkers, which help clinicians in decision-making and management of patients.
- Open Access
- 16 December 2023
- Published by Wiley in Acta Paediatrica
- Vol. 113 (4) , 771-777
The changing clinical presentation of COVID‐19 in children during the course of the pandemic
Aim: To investigate the evolution of clinical symptoms of COVID‐19 in children throughout the pandemic.Methods: In this national prospective surveillance study, symptoms in children hospitalised with COVID‐19 were collected from all paediatric hospitals in Switzerland between March 2020 and March 2023. Data was analysed across four time periods, according to the predominantly circulating SARS‐CoV‐2 variant: T1 (wild‐type), T2 (Alpha), T3 (Delta) and T4 (Omicron), as well as by age group.Results: The study included 1323 children. The proportion of children admitted to an intensive care unit remained stable throughout the pandemic. However, the pattern and frequency of clinical manifestations changed over time. Respiratory symptoms were less prevalent during T1 (wild‐type), fever during T2 (Alpha) and rash during T4 (Omicron). In contrast, fever and neurological symptoms were more prevalent during T4 (Omicron). Newly described symptoms during T4 (Omicron) included conjunctivitis, laryngotracheitis and seizures. Fever was more prevalent among neonates and infants whereas respiratory symptoms were more common among infants. Gastrointestinal symptoms were more frequent among toddlers, while both toddlers and school‐aged children presented with neurological symptoms more often than other age groups.Conclusion: Continuous surveillance is required to detect changes in manifestations and there by be prepared for the optimal management of complications in children with COVID‐19.
- 16 December 2023
- Published by Wiley in Acta Paediatrica
- Vol. 113 (4) , 771-777
Open AccessThe changing clinical presentation of COVID‐19 in children during the course of the pandemic
Aim: To investigate the evolution of clinical symptoms of COVID‐19 in children throughout the pandemic.Methods: In this national prospective surveillance study, symptoms in children hospitalised with COVID‐19 were collected from all paediatric hospitals in Switzerland between March 2020 and March 2023. Data was analysed across four time periods, according to the predominantly circulating SARS‐CoV‐2 variant: T1 (wild‐type), T2 (Alpha), T3 (Delta) and T4 (Omicron), as well as by age group.Results: The study included 1323 children. The proportion of children admitted to an intensive care unit remained stable throughout the pandemic. However, the pattern and frequency of clinical manifestations changed over time. Respiratory symptoms were less prevalent during T1 (wild‐type), fever during T2 (Alpha) and rash during T4 (Omicron). In contrast, fever and neurological symptoms were more prevalent during T4 (Omicron). Newly described symptoms during T4 (Omicron) included conjunctivitis, laryngotracheitis and seizures. Fever was more prevalent among neonates and infants whereas respiratory symptoms were more common among infants. Gastrointestinal symptoms were more frequent among toddlers, while both toddlers and school‐aged children presented with neurological symptoms more often than other age groups.Conclusion: Continuous surveillance is required to detect changes in manifestations and there by be prepared for the optimal management of complications in children with COVID‐19.
- Open Access
- 25 October 2023
- Published by Wiley in Acta Paediatrica
- Vol. 113 (1) , 116-118
Day care study showed no differences in long‐term symptoms in children who were and were not infected during COVID‐19 outbreaks
- 25 October 2023
- Published by Wiley in Acta Paediatrica
- Vol. 113 (1) , 116-118
Open AccessDay care study showed no differences in long‐term symptoms in children who were and were not infected during COVID‐19 outbreaks
- Open Access
- 8 July 2022
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 150, e141
Transmission of SARS-CoV-2 among children and staff in German daycare centres
In daycare centres, the close contact of children with other children and employees favours the transmission of infections. The majority of children vs. 5.1% with evidence of wild type). The household SAR was 53.3%. Exposed daycare children were less likely to get infected with SARS-CoV-2 than employees (7.7% vs. 15.5%). Containment measures in daycare programmes are critical to reduce SARS-CoV-2 transmission, especially to avoid spread to associated households.
- 8 July 2022
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 150, e141
Open AccessTransmission of SARS-CoV-2 among children and staff in German daycare centres
In daycare centres, the close contact of children with other children and employees favours the transmission of infections. The majority of children vs. 5.1% with evidence of wild type). The household SAR was 53.3%. Exposed daycare children were less likely to get infected with SARS-CoV-2 than employees (7.7% vs. 15.5%). Containment measures in daycare programmes are critical to reduce SARS-CoV-2 transmission, especially to avoid spread to associated households.